Antigen Information

General Information of This Antigen

Antigen ID	TAR0SYQPS
Antigen Name	Programmed cell death 1 ligand 1 (CD274)
Gene Name	CD274
Synonym1	B7H1, PDCD1L1, PDCD1LG1, PDL1
Sequence1	MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV Click to Show/Hide
Family1	BTN/MOG family
Function1	The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. Click to Show/Hide
Uniprot Entry	PD1L1_HUMAN
HGNC ID	HGNC:17635
KEGG ID	hsa:29126

Each Antibody-drug Conjuate AND It's Component Related to This Antigen

Full List of The ADC Related to This Antigen

Anti-mouse PD-L1 (B7-H1)

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	wO2023232144A1ADC38	WO2025015586A1, ADC34, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	Mc-Val-Cit-PABC	[1]
ADC Info	wO2023232144A1ADC39	WO2025015586A1, ADC35, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	Mc-Val-Cit-PABC	[1]
ADC Info	wO2023232144A1ADC40	WO2025015586A1, ADC34, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	SMCC	[1]
ADC Info	wO2023232144A1ADC41	WO2025015586A1, ADC35, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	SMCC	[1]

Atezolizumab

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	PD-L1 ADC 3	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Ala-PABC	[2]
ADC Info	Atezolizumab ADC	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[2]
ADC Info	PDL1-Dox ADC	Doxorubicin	DNA topoisomerase 2-alpha (TOP2A)	Undisclosed	[3]
ADC Info	40460724 ADC A9	Undisclosed	Undisclosed	Undisclosed	[4]
ADC Info	40460724 ADC A10	Undisclosed	Undisclosed	Undisclosed	[4]
ADC Info	Pemetrexed-GABA-mAb conjugate	Pemetrexed	Undisclosed	Gamma-Aminobutyric acid (GABA)	[5]
ADC Info	Pemetrexed-PEG-mAb conjugate	Pemetrexed	Undisclosed	NH2-PEG4-COOH	[5]
ADC Info	39914224 Ate-36	Monomethyl auristatin E	Undisclosed	Phenoxy silyl linker 36	[6]
ADC Info	39914224 Ate-37	Monomethyl auristatin E	Undisclosed	Phenoxy silyl linker 37	[6]
ADC Info	39914224 Ate-38	Monomethyl auristatin E	Undisclosed	Phenoxy silyl linker 38	[6]
ADC Info	39914224 Ate-39	Monomethyl auristatin E	Undisclosed	Phenoxy silyl linker 39	[6]
ADC Info	Atezolizumab-Immunoconjugate A	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate B	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate C	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate D	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate E	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate F	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate G	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate H	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate I	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate J	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate L	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate M	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate N	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate O	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate P	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate Q	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate R	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate S	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate T	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate U	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate V	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Atezolizumab-Immunoconjugate K1	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	US20220226491A1 Immunoconjugate R1	undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	tW202436324A ADC-1.1	TW202436324A+ADC-1.1+payload	Undisclosed	Mal-PEG2-Val-Cit-PAB	[8]
ADC Info	tW202436324A ADC-1.2	TW202436324A+ADC-1.1+payload	Undisclosed	Mal-PEG2-Val-Cit-PAB	[8]
ADC Info	tW202436324A ADC-1.3	TW202436324A+ADC-1.1+payload	Undisclosed	Mal-PEG2-Val-Cit-PAB	[8]
ADC Info	tW202436324A ADC-1.4	TW202436324A+ADC-1.1+payload	Undisclosed	Mal-PEG2-Val-Cit-PAB	[8]
ADC Info	tW202436324A ADC-1.5	TW202436324A+ADC-1.1+payload	Undisclosed	Mal-PEG2-Val-Cit-PAB	[8]
ADC Info	tW202436324A ADC-1.6	TW202436324A+ADC-1.1+payload	Undisclosed	Mal-PEG2-Val-Cit-PAB	[8]
ADC Info	tW202436324A ADC-2	TW202436324A+ADC-2+payload	Undisclosed	TW202436324A+ADC-2+Linker	[8]
ADC Info	tW202436324A ADC-3.1	TW202436324A+ADC-3.1payload	Undisclosed	Mc-Val-Cit-PABC	[8]
ADC Info	tW202436324A ADC-3.2	TW202436324A+ADC-3.1payload	Undisclosed	Mc-Val-Cit-PABC	[8]
ADC Info	tW202436324A ADC-3.3	TW202436324A+ADC-3.1payload	Undisclosed	Mc-Val-Cit-PABC	[8]
ADC Info	tW202436324A ADC-3.4	TW202436324A+ADC-3.1payload	Undisclosed	Mc-Val-Cit-PABC	[8]
ADC Info	tW202436324A ADC-4	TW202436324A+ADC-4+payload	Undisclosed	Mc-Val-Cit-PABC	[8]
ADC Info	tW202436324A ADC-5	TW202436324A+ADC-1.1+payload	Undisclosed	TW202436324A+ADC-5+Linker	[8]
ADC Info	tW202436324A ADC-6	TW202436324A+ADC-1.1+payload	Undisclosed	TW202436324A+ADC-6+Linker	[8]
ADC Info	tW202436324A ADC-7	TW202436324A+ADC-1.1+payload	Undisclosed	TW202436324A+ADC-7+Linker	[8]
ADC Info	cN115364238B Compound 4	CN115364238B+Compound 4+payload	Undisclosed	CN115364238B+Compound 4+Linker	[9]
ADC Info	wO2023232144A1ADC44	WO2025015586A1, ADC35, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	SMCC	[1]

Avelumab

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	PD-L1 ADC 1	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Ala-PABC	[2]
ADC Info	PD-L1 ADC 2	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[2]
ADC Info	ADC HE-S2	Bifunctional immunomodulator D18	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	Disulfide linker 8	[10]
ADC Info	AU2020291014A1 IC-9	AU2020291014A1-Payload-70	Undisclosed	Aminobenzazepine-linker Formula II-15	[11]
ADC Info	AU2020291014A1 IC-15	Undisclosed	Undisclosed	Undisclosed	[11]
ADC Info	WO2024105206A1 23p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 29p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 30p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 31p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 32p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 34p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 36p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 37p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 38p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 39p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 40p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 42p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 43p-Avelu 1	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 23p-Avelu 2	Mdo-cpt	DNA topoisomerase I (TOP1)	23i-5657 Linker	[12]
ADC Info	wO2023232144A1ADC26	WO2025015586A1, ADC22, Payload	DNA topoisomerase I (TOP1)	Mc-Val-Cit-PABC	[1]
ADC Info	wO2023232144A1ADC27	WO2025015586A1, ADC23, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	Mc-Val-Cit-PABC	[1]
ADC Info	wO2023232144A1ADC28	WO2025015586A1, ADC24, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	Mc-Val-Cit-PABC	[1]
ADC Info	wO2023232144A1ADC29	WO2025015586A1, ADC25, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	Mc-Val-Cit-PABC	[1]
ADC Info	wO2023232144A1ADC31	WO2025015586A1, ADC25, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	SMCC	[1]
ADC Info	wO2023232144A1ADC33	WO2025015586A1, ADC22, Payload	DNA topoisomerase I (TOP1)	SMCC	[1]
ADC Info	wO2023232144A1ADC42	WO2025015586A1, ADC34, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	SMCC	[1]
ADC Info	wO2023232144A1ADC43	WO2025015586A1, ADC35, Payload	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	SMCC	[1]
ADC Info	wO2024105206A1 1p-Avelu	CHH0170, 1i-5657, Payload	Undisclosed	32p-Avelu Linker	[12]

Bavdegalimab

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	jP7560255B2 ControlADC54	Undisclosed	Undisclosed	Undisclosed	[13]

Bavencio

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	tWI857167B IC-4	TWI857167B-IC-2-PAYLOAD	Undisclosed	TWI857167B-IC-1-LINKER	[14]
ADC Info	tWI857167B IC-5	TWI857167B-IC-3-PAYLOAD	Undisclosed	Aminobenzazepine-linker Formula II-3	[14]

bsCTRL×HER2

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	bsCTRL×HER2-DXd	DX-8951 derivative (DXd)	DNA topoisomerase 1 (TOP1)	Undisclosed	[15]

bsSORT1×CTRL

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	bsSORT1×CTRL-DXd	DX-8951 derivative (DXd)	DNA topoisomerase 1 (TOP1)	Undisclosed	[15]

bsSORT1×HER2

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	bsSORT1×HER2-DXd	DX-8951 derivative (DXd)	DNA topoisomerase 1 (TOP1)	Undisclosed	[15]

PDL1.24-GIF

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	tWI857167B IC-8	TWI857167B-IC-2-PAYLOAD	Undisclosed	TWI857167B-IC-1-LINKER	[14]

PDL1.85-GIF

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	tWI857167B IC-9	TWI857167B-IC-2-PAYLOAD	Undisclosed	TWI857167B-IC-1-LINKER	[14]

TPP-Avelumab

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	WO2024105206A1 29p-Avelu 2	Mdo-cpt	DNA topoisomerase I (TOP1)	29p-Avelu Linker	[12]
ADC Info	WO2024105206A1 30p-Avelu 2	22i-5657 Payload	Undisclosed	22i-5657 Linker	[12]
ADC Info	WO2024105206A1 31p-Avelu 2	41i-5657 Payload	Undisclosed	31p-Avelu Linker	[12]
ADC Info	WO2024105206A1 32p-Avelu 2	Mdo-cpt	DNA topoisomerase I (TOP1)	32p-Avelu Linker	[12]
ADC Info	WO2024105206A1 34p-Avelu 2	Monomethyl auristatin E	Microtubule (MT)	22i-5657 Linker	[12]
ADC Info	WO2024105206A1 36p-Avelu 2	Camptothecin	Undisclosed	36p-Avelu Linker	[12]
ADC Info	WO2024105206A1 37p-Avelu 2	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 38p-Avelu 2	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 39p-Avelu 2	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 40p-Avelu 2	Camptothecin	Undisclosed	40i-5657 Linker	[12]
ADC Info	WO2024105206A1 42p-Avelu 2	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	WO2024105206A1 43p-Avelu 2	Undisclosed	Undisclosed	Undisclosed	[12]

Undisclosed

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	YB1-ADC-PDL1	Undisclosed	Undisclosed	Undisclosed	[16]
ADC Info	OX-001L ADC	Undisclosed	Undisclosed	Undisclosed	[17]
ADC Info	OX-003	Undisclosed	Undisclosed	Undisclosed	[18]
ADC Info	BDB-101	TLR7/8 agonist	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	Undisclosed	[19]
ADC Info	PD-L1 ISA	TLR7/8 agonist	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)	Undisclosed	[20]

undisclosed

Antibody Info

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Anti-PDL1-PBA-Cur	PBA-Cur	Undisclosed	Undisclosed	[21]
ADC Info	aPDL1-NPLG-SN38	Active metabolite of irinotecan SN38	Undisclosed	NPLG	[22]
ADC Info	cN114786729A ADC-I	CDN-B	Undisclosed	CN114786729A-ADC-I-Linker	[23]
ADC Info	cN114786729A ADC-II	CDN-A	Undisclosed	Mc-Val-Cit-PABC	[23]
ADC Info	cN114786729A ADC-III	CDN-B	Undisclosed	Undisclosed	[23]
ADC Info	cN114786729A ADC-IV	CDN-B	Undisclosed	Undisclosed	[23]
ADC Info	cN114786729A ADC-V	CDN-A	Undisclosed	Undisclosed	[23]
ADC Info	cN114786729A ADC-VI	CDN-A	Undisclosed	Undisclosed	[23]
ADC Info	pF-08046054	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC

References

Ref 1	Drug conjugates of imidazoquinoline amine derivatives, compositions and methods thereof
Ref 2	Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. Bioorg Chem. 2021 Nov;116:105366.
Ref 3	PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer. Cancers (Basel). 2019 Feb 16;11(2):232. doi: 10.3390/cancers11020232.
Ref 4	Triptolide-based cleavable antibody-drug conjugates for pancreatic cancer
Ref 5	Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates
Ref 6	Fine-tuning phenoxy silyl scaffolds for the development of glutathione-responsive prodrugs and antibody-drug conjugates
Ref 7	Immunoconjugates targeting PD-L1
Ref 8	A linker, antibody-drug conjugates comprising the linker, and preparation methods and uses
Ref 9	An atezolizumab-MMAD conjugate and its preparation method and uses
Ref 10	Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021 Nov 11;64(21):15716-15726. doi: 10.1021/acs.jmedchem.1c00961. Epub 2021 Nov 3.
Ref 11	Aminobenzazepine compounds, immunoconjugates, and uses thereof
Ref 12	Antibody-drug conjugates cleavable in a tumor microenvironment
Ref 13	Pharmaceuticals containing antibody-drug complexes containing hemiasterin derivatives
Ref 14	Thienobenzodiazepine immunoconjugates and uses thereof
Ref 15	Generation of a Novel SORT1×HER2 Bispecific Antibody-Drug Conjugate Targeting HER2-Low-Expression Tumor
Ref 16	YB1 pharmaceutical company product pipeline
Ref 17	Harnessing novel immune escape mechanisms for cancer therapeutics: OXAB1 target validation, proof of concept and preclinical development; 2018.
Ref 18	Oxford BioTherapeutics designates second bispecific antibody program leveraging WuXi Biologics's WuXiBody platform; 2021.
Ref 19	Seven and eight biopharmaceutical company produce pipeline
Ref 20	PD-L1-targeted ISAC combines myeloid cell activation, immune checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models; 2021
Ref 21	Preparation and anti-tumor ability evaluation of anti-PD-L1 conjugated curcumin in colon cancer
Ref 22	Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy
Ref 23	Antibody-STING agonist conjugates and their use in immunotherapy

Antigen Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)